Pretax income is the income that a company earns before paying income taxes. CytoMed Therapeutics's pretax income for the
six
months ended in Dec. 2023 was $-1.48 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.09 Mil.
CytoMed Therapeutics's pretax margin was %.
CytoMed Therapeutics Pre-Tax Income Historical Data
The historical data trend for CytoMed Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of CytoMed Therapeutics's Pre-Tax Income
For the Biotechnology subindustry, CytoMed Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoMed Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytoMed Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where CytoMed Therapeutics's Pre-Tax Income falls into.
CytoMed Therapeutics Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
CytoMed Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-3.09 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoMed Therapeutics (NAS:GDTC) Pre-Tax Income Explanation
CytoMed Therapeutics's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoMed Therapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of CytoMed Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
CytoMed Therapeutics (CytoMed Therapeutics) Business Description
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies into creating novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is majority revenue generator.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GDTC has been successfully added to your